EG vs PRE vs EXAS vs RNR

For growth investors, Prenetics Global Limited (PRE) is the stronger pick with 201.

7% revenue growth year-over-year, versus 1. 4% for Everest Re Group, Ltd. (EG). RenaissanceRe Holdings Ltd. (RNR) offers the better valuation at 5. 3x trailing P/E (7. 7x forward), making it the more compelling value choice. Analysts rate Prenetics Global Limited (PRE) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, RenaissanceRe Holdings Ltd.

(RNR) is the cheapest at 5. 3x versus Everest Re Group, Ltd. at 9. 3x. On forward P/E, Everest Re Group, Ltd. is actually cheaper at 6. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: RenaissanceRe Holdings Ltd. wins at 0. 26x versus Everest Re Group, Ltd. 's 0. 28x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, RenaissanceRe Holdings Ltd.

(RNR) delivered a total return of +87. 1%, compared to -86. 1% for Prenetics Global Limited (PRE). Over 10 years, the gap is even starker: EXAS returned +1669% versus PRE's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), RenaissanceRe Holdings Ltd.

(RNR) is the lower-risk stock at -0. 03β versus Everest Re Group, Ltd. 's 0. 36β — meaning EG is approximately -1244% more volatile than RNR relative to the S&P 500. On balance sheet safety, Prenetics Global Limited (PRE) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Prenetics Global Limited (PRE) is pulling ahead at 201.

7% versus 1. 4% for Everest Re Group, Ltd. (EG). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -14. 0% for Prenetics Global Limited. Over a 3-year CAGR, PRE leads at 91. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

RenaissanceRe Holdings Ltd.

(RNR) is the more profitable company, earning 21. 0% net margin versus -63. 1% for Prenetics Global Limited — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNR leads at 31. 5% versus -40. 5% for PRE. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, RenaissanceRe Holdings Ltd. (RNR) is the more undervalued stock at a PEG of 0. 26x versus Everest Re Group, Ltd. 's 0. 28x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Everest Re Group, Ltd. (EG) trades at 6. 7x forward P/E versus 582. 8x for Exact Sciences Corporation — 576. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRE: 126. 8% to $36. 00.

In this comparison, EG (2.

3% yield), RNR (0. 6% yield) pay a dividend. PRE, EXAS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, PRE: -86. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EG (Financial Services) and PRE (Healthcare) and EXAS (Healthcare) and RNR (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EG is a mid-cap deep-value stock; PRE is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; RNR is a mid-cap deep-value stock. EG, RNR pay a dividend while PRE, EXAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.